Clinical trials: Cancer, Gastrointestinal
Healthy Participants, Gastrointestinal Neoplasms
A Study to Investigate the Effects of Impaired Hepatic Function on Velzatinib
This study evaluates the pharmacokinetics (PK), safety, and tolerability of velzatinib in participants with mild, moderate, and severe hepatic impairment (HI) and participants with normal hepatic function.
- Trial name
- NCT07859735
- Testing
- Velzatinib
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Colorectal Cancer
A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
This study will assess the efficacy and safety of continuous oral Xeloda administration in combination with intravenous irinotecan as a first-line treatment in patients with advanced and/or metastatic colorectal cancer.
- Trial name
- NCT00048126
- Testing
- Irinotecan, capecitabine [Xeloda]
- Where
- 10 sites in United States
- Volunteers
- 57 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor, Metastatic Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05267626
- Testing
- AU-007, Aldesleukin, Avelumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Aulos Bioscience, Inc.
Cancer, Solid Tumor
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.
- Conditions
- Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05704985
- Testing
- DK210 (EGFR), Radiation therapy, Immune checkpoint blockers
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- DEKA Biosciences
PTCH1 or SMO Activated Solid and Hematologic Tumors
LDE225 for Patients With PTCH1 or SMO Mutated Tumors
The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study
- Trial name
- SIGNATURE (NCT02002689)
- Testing
- LDE225
- Where
- 10 sites in United States
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
This prospective observational study will evaluate the efficacy and safety of bevacizumab in combination with capecitabine and oxaliplatin as first-line treatment in participants with colorectal cancer.
- Trial name
- NCT01399190
- Testing
- Bevacizumab, Capecitabine, Oxaliplatin
- Where
- 9 sites in Slovakia
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Neoplasms
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
To evaluate the efficacy and safety of TQB2868 injection combined with anlotinib capsule and chemotherapy in treated patients with Pancreatic Neoplasms
- Trial name
- NCT06767813
- Testing
- TQB2868 injection, Gemcitabine injection, Albumin paclitaxel injection
- Where
- 7 sites in China
- Volunteers
- 80 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Advanced Malignancy, Advanced Solid Tumors
Safety Study of AMG 228 to Treat Solid Tumors
The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology
- Trial name
- NCT02437916
- Testing
- AMG 228
- Where
- 7 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Amgen
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Colorectal Cancer
Paired Analysis of Sensitivity for Colorectal Cancer Using COLVERA : PASCAL
To compare the sensitivity and specificity estimates of Colvera with that of a commercially available CEA test for detection of recurrent disease in subjects with colorectal cancer that have documented recurrence or no evidence…
- Trial name
- PASCAL (NCT03706248)
- Testing
- Blood Draw
- Where
- 6 sites in United States
- Volunteers
- 65 people
- Sponsor
- Clinical Genomics Pathology
Gastrointestinal Stromal Tumors
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
To evaluate the antitumor activity of SU011248 in advanced, imatinib mesylate-resistant gastrointestinal stromal tumor (GIST) when administered on a continuous daily dosing schedule
- Trial name
- NCT00137449
- Testing
- SU011248
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 60 people
- Sponsor
- Pfizer
Gastrointestinal Cancer
Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma
This is a phase 2, randomized, double blind, placebo controlled, multi-center study to estimate the improvement in progression free survival (compared to control subjects) and evaluate the safety and tolerability of AMG 386 in…
- Trial name
- NCT00583674
- Testing
- AMG 386 10mg/kg, AMG 386 3mg/kg, Cisplatin
- Volunteers
- 171 people
- Sponsor
- Amgen
Rectal Neoplasms
A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.
The purpose of this study is to help answer the following research questions: If the study drug Pemetrexed can help patients with rectal cancer; If molecular biological parameters are correlated respectively changing due to…
- Trial name
- NCT00330915
- Testing
- pemetrexed
- Where
- Sweden
- Volunteers
- 37 people
- Sponsor
- Eli Lilly and Company
Barrett's Esophagus
Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System
The NvisionVLE® Dysplasia Detection Pilot Study is a prospective, non-randomized trial for participants who have a prior biopsy-confirmed diagnosis of BE with dysplasia and are scheduled to have an endoscopic evaluation of your…
- Trial name
- DDP (NCT02864043)
- Testing
- NvisionVLE with Real Time Targeting, esophagogastroduodenoscopy (EGD)
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- NinePoint Medical
Cancer
Clinical Study of Pan-cancer DNA Methylation Test in Plasma
We intend to establish an efficient method for plasma cfDNA extraction and Bisulfite transformation to facilitate the detection of DNA methylation status using multiplex fluorescence PCR.
- Trial name
- NCT05685524
- Testing
- DNA methylation test
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Wuhan Ammunition Life-tech Co., Ltd
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Neoplasms Malignant
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
This is an open-label, two-part study to evaluate the safety and tolerability of combination treatment with dalotuzumab + MK-2206, dalotuzumab + MK-0752, or dalotuzumab + ridaforolimus (MK-8669).
- Trial name
- NCT01243762
- Testing
- dalotuzumab, MK-0752, ridaforolimus
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer in Patients Under 50 Years of Age, Colorectal Cancer
Colorectal Cancer in Young Adults: Study of Incidence, Survival, and Prognostic Factors in Tarragona, Spain
We conducted an observational, descriptive, longitudinal and retrospective study of 59 patients under 50 years of age diagnosed with CRC in the province of Tarragona, between 2019 and 2024.
- Trial name
- CCR50 (NCT07026955)
- Testing
- colorectal cancer in patients over 50 years of age
- Where
- Spain
- Volunteers
- 59 people
- Sponsor
- HJ23
Biliary Tract Cancer
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
This is a multicenter, Phase 2 clinical trial to evaluate the efficacy and safety, PK and immunogenicity of SHR-A1904 in patients with advanced or metastatic biliary tract cancer (BTC).
- Trial name
- NCT07450976
- Testing
- SHR-A1904 for Injection
- Where
- 2 sites in China
- Volunteers
- 151 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.